Literature DB >> 29623482

Nivolumab-induced acute granulomatous tubulointerstitial nephritis in a patient with gastric cancer.

Yoshihisa Nakatani1, Hisato Kawakami2, Masashi Ichikawa1, Sachiyo Yamamoto1, Yasuo Otsuka3, Akiko Mashiko1, Yasutoshi Takashima4, Akihiko Ito4, Kazuhiko Nakagawa3, Shuji Arima1.   

Abstract

We here report a case of nivolumab-induced acute granulomatous tubulointerstitial nephritis in a patient with gastric cancer. A 68-year-old woman with recurrent gastric cancer developed acute kidney injury associated with kidney enlargement and urinary leukocytes after 38 cycles of nivolumab treatment. A diagnosis of acute granulomatous tubulointerstitial nephritis was made based on kidney biopsy findings. Immunohistochemistry revealed expression of programmed cell death-ligand 1 (PD-L1) in degenerated epithelial cells of collecting tubules. Among infiltrating immune cells, aggregation of T cells was more extensive than that of B cells, with CD4+ T cells outnumbering CD8+ T cells, consistent with the relative numbers of these cells in the circulation. Treatment with methylprednisolone (1.0 mg/kg daily) led to a rapid improvement in renal function and reduction in the number of circulating CD4+ T cells. Prompt administration of high-dose corticosteroid is thus recommended after diagnosis of this adverse event of nivolumab treatment by kidney biopsy.

Entities:  

Keywords:  Gastric cancer; Granulomatous tubulointerstitial nephritis; Nivolumab

Mesh:

Substances:

Year:  2018        PMID: 29623482     DOI: 10.1007/s10637-018-0596-7

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  11 in total

Review 1.  MHC class II, antigen presentation and tumor necrosis factor in renal tubular epithelial cells.

Authors:  R P Wuthrich; L H Glimcher; M A Yui; A M Jevnikar; S E Dumas; V E Kelley
Journal:  Kidney Int       Date:  1990-02       Impact factor: 10.612

2.  Expression of B7-H1 in inflammatory renal tubular epithelial cells.

Authors:  Yongwen Chen; Jingbo Zhang; Jingyi Li; Liyun Zou; Tingting Zhao; Yan Tang; Yuzhang Wu
Journal:  Nephron Exp Nephrol       Date:  2005-11-11

3.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

Authors:  Julie R Brahmer; Charles G Drake; Ira Wollner; John D Powderly; Joel Picus; William H Sharfman; Elizabeth Stankevich; Alice Pons; Theresa M Salay; Tracee L McMiller; Marta M Gilson; Changyu Wang; Mark Selby; Janis M Taube; Robert Anders; Lieping Chen; Alan J Korman; Drew M Pardoll; Israel Lowy; Suzanne L Topalian
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

Review 4.  Renal effects of immune checkpoint inhibitors.

Authors:  Hassan Izzedine; Christine Mateus; Céline Boutros; Caroline Robert; Philippe Rouvier; Zahir Amoura; Alexis Mathian
Journal:  Nephrol Dial Transplant       Date:  2017-06-01       Impact factor: 5.992

5.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

6.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

7.  Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Yoon-Koo Kang; Narikazu Boku; Taroh Satoh; Min-Hee Ryu; Yee Chao; Ken Kato; Hyun Cheol Chung; Jen-Shi Chen; Kei Muro; Won Ki Kang; Kun-Huei Yeh; Takaki Yoshikawa; Sang Cheul Oh; Li-Yuan Bai; Takao Tamura; Keun-Wook Lee; Yasuo Hamamoto; Jong Gwang Kim; Keisho Chin; Do-Youn Oh; Keiko Minashi; Jae Yong Cho; Masahiro Tsuda; Li-Tzong Chen
Journal:  Lancet       Date:  2017-10-06       Impact factor: 79.321

8.  Acute interstitial nephritis related to immune checkpoint inhibitors.

Authors:  Julie Belliere; Nicolas Meyer; Julien Mazieres; Sylvie Ollier; Serge Boulinguez; Audrey Delas; David Ribes; Stanislas Faguer
Journal:  Br J Cancer       Date:  2016-11-10       Impact factor: 7.640

9.  Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor.

Authors:  Julia Escandon; Stephanie Peacock; Asaad Trabolsi; David B Thomas; Ayman Layka; Jose Lutzky
Journal:  J Immunother Cancer       Date:  2017-01-17       Impact factor: 13.751

10.  Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer.

Authors:  Koji Haratani; Hidetoshi Hayashi; Yasutaka Chiba; Keita Kudo; Kimio Yonesaka; Ryoji Kato; Hiroyasu Kaneda; Yoshikazu Hasegawa; Kaoru Tanaka; Masayuki Takeda; Kazuhiko Nakagawa
Journal:  JAMA Oncol       Date:  2018-03-01       Impact factor: 31.777

View more
  5 in total

1.  Reintroduction of nivolumab in a patient with gastric cancer after improvement of nivolumab-induced acute interstitial nephritis: a case report.

Authors:  Qingjiang Hu; Hirofumi Hasuda; Kenji Ueki; Akihiro Tsuchimoto; Yoko Zaitsu; Yasuo Tsuda; Yuichi Hisamatsu; Yuichiro Nakashima; Koji Ando; Yasue Kimura; Eiji Oki; Masaki Mori
Journal:  Int Cancer Conf J       Date:  2020-05-22

2.  Antitumor evaluation of novel phenothiazine derivatives that inhibit migration and tubulin polymerization against gastric cancer MGC-803 cells.

Authors:  Nan Liu; Zhe Jin; Jing Zhang; Jianjun Jin
Journal:  Invest New Drugs       Date:  2018-10-22       Impact factor: 3.850

3.  Valproic Acid Induces Endothelial-to-Mesenchymal Transition-Like Phenotypic Switching.

Authors:  Shamini Murugavel; Antoinette Bugyei-Twum; Pratiek N Matkar; Husain Al-Mubarak; Hao H Chen; Mohamed Adam; Shubha Jain; Tanya Narang; Rawand M Abdin; Mohammad Qadura; Kim A Connelly; Howard Leong-Poi; Krishna K Singh
Journal:  Front Pharmacol       Date:  2018-07-11       Impact factor: 5.810

Review 4.  PD-1 immunobiology in glomerulonephritis and renal cell carcinoma.

Authors:  Colleen S Curran; Jeffrey B Kopp
Journal:  BMC Nephrol       Date:  2021-03-06       Impact factor: 2.388

Review 5.  Management of acute kidney injury in gastrointestinal tumor: An overview.

Authors:  Yi-Qi Su; Yi-Yi Yu; Bo Shen; Feng Yang; Yu-Xin Nie
Journal:  World J Clin Cases       Date:  2021-12-16       Impact factor: 1.337

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.